Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Sets Up Committee For Pharmaceutical Research Intellectual Property Rights

This article was originally published in PharmAsia News

Executive Summary

Chinese Pharmaceutical Association's Committee for Pharmaceutical Research Intellectual Property Rights, the first professional organization in the field, recently held its first plenary meeting in Beijing. The committee was set up with the objectives of bridging communication among authorities, societies, pharmaceutical enterprises and public institutions; providing advice on IP rights strategy for the nation, pharmaceutical industry and enterprises; and offering consultations for China's decision makers. Its role will be to promote the establishment of a scientific, rational and strict pharmaceutical IP rights system to support pharmaceutical innovation; provide advice for the industry and government by initiating research on TCM IP rights in international trading; and groom technical expertise in a planned and systematic way. (Click here for more - Chinese language)

You may also be interested in...



Lannett Reports Insulin Glargine Trial Success

Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.

BREAKING: Sanofi Forms Standalone Consumer Healthcare Unit: Prelude To Spin-Off?

Sanofi Consumer Healthcare is to operate as a standalone unit in a move which is being viewed as a prelude to a potential spin-off. High profile prescription-to-OTC switches are a priority for the revamped business. 

Data Integrity Remains Challenging For API Manufacturers

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.

UsernamePublicRestriction

Register

SC072299

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel